Position in BIIB
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$370,758
-$94,167 QoQ
Shares Held
1,716
-48.3% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.09%
of 13F equity value
Holder Rank
#628
of 1,031 holders
Holding Since
Mar 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in BIIB Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026EntryPoint Capital, LLC holds $4,359,430 across 8 Drug Manufacturers - General names. BIIB ranks #3 (8.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | GILD |
Gilead Sciences, Inc.
|
13,595 | $1,717,592 | |
| 2 | PFE |
Pfizer Inc
|
40,976 | $986,702 | |
| 3 | BIIB |
Biogen Inc.
This page
|
1,716 | $370,758 | |
| 4 | GSK |
GSK plc
|
6,632 | $347,649 | |
| 5 | NVS |
Novartis AG
|
1,936 | $303,409 | |
| 6 | AMGN |
Amgen Inc
|
654 | $236,826 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
3,499 | $201,612 | |
| 8 | AMRN |
Amarin Corp Plc\Uk
|
12,226 | $194,882 |
All Filings in BIIB
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $370,758 | 1,716 | Shares | Sole | 2026-08-13 | |
| 2025-09-30 | $464,925 | 3,319 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $384,430 | 3,061 | Shares | Sole | 2025-08-11 | |
| 2025-03-31 | $435,014 | 3,179 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $250,635 | 1,639 | Shares | Sole | 2025-02-11 | |
| 2024-09-30 | $307,042 | 1,584 | Shares | Sole | 2024-11-13 | |
| 2024-03-31 | $36,010 | 167 | Shares | Sole | 2024-05-14 | |
| No filing history on record for this holder in this stock. | ||||||